-rubicin

Anthracyclines (the '-rubicin' drug class) work by multiple mechanisms: (1) intercalating into DNA to disrupt replication and transcription, (2) inhibiting topoisomerase II, leading to DNA strand breaks, and (3) generating free radicals that cause oxidative damage to DNA and cell membranes. They are widely used in treating leukemias (daunorubicin, idarubicin), lymphomas, and solid tumors such as breast cancer and sarcomas (doxorubicin).

Key clinical significance for boards: Dose-dependent, cumulative cardiotoxicity is the hallmark adverse effect, mediated by free radical formation and lipid peroxidation in cardiac myocytes, which have relatively low antioxidant defenses. This can manifest as dilated cardiomyopathy and congestive heart failure, sometimes occurring months to years after treatment. Dexrazoxane, an iron-chelating agent, is used to reduce the risk of cardiotoxicity by limiting free radical formation.

Other notable toxicities include myelosuppression (common to many chemotherapeutics), alopecia, and a distinctive 'radiation recall' phenomenon. Doxorubicin and daunorubicin also cause red-orange discoloration of urine, which is a harmless but important point to counsel patients about.

Mechanistically, these drugs are cell-cycle non-specific but show increased activity during S phase due to topoisomerase II interaction during DNA replication. Resistance can develop via P-glycoprotein-mediated drug efflux (MDR1 gene overexpression).

High-yield associations: doxorubicin + cardiotoxicity (test with echocardiogram or MUGA scan before and during treatment), dexrazoxane as cardioprotective agent, and the suffix '-rubicin' as a mnemonic for anthracyclines on pharmacology sections of USMLE Step 1.